Edition:
India

Catalyst Biosciences Inc (CBIO.OQ)

CBIO.OQ on NASDAQ Stock Exchange Capital Market

14.54USD
10:05pm IST
Change (% chg)

$0.36 (+2.54%)
Prev Close
$14.18
Open
$14.15
Day's High
$14.66
Day's Low
$13.85
Volume
11,537
Avg. Vol
58,764
52-wk High
$18.88
52-wk Low
$3.13

Chart for

About

Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and... (more)

Overall

Beta: 1.35
Market Cap(Mil.): $24.57
Shares Outstanding(Mil.): 4.31
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.11 16.44
EPS (TTM): -- -- --
ROI: -- 14.85 10.61
ROE: -- 16.31 14.21

BRIEF-Catalyst Biosciences Initiates Phase 2/3 Trial Of Marzeptacog Alfa (Activated)

* CATALYST BIOSCIENCES INITIATES PHASE 2/3 TRIAL OF MARZEPTACOG ALFA (ACTIVATED) FOR PROPHYLAXIS IN HEMOPHILIA A OR B WITH INHIBITORS

04 Jan 2018

BRIEF-Nexthera Capital Reports 5.4 Pct Passive Stake In Catalyst Biosciences

* NEXTHERA CAPITAL REPORTS A 5.4 PERCENT PASSIVE STAKE IN CATALYST BIOSCIENCES AS OF DEC 20 - SEC FILING Source text : (http://bit.ly/2l9OsLV) Further company coverage:

28 Dec 2017

BRIEF-Catalyst Biosciences Announces Pricing Of Public Offering Of Common Stock

* CATALYST BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

20 Dec 2017

BRIEF-Catalyst Biosciences Announces Proposed Public Offering Of Common Stock

* CATALYST BIOSCIENCES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

20 Dec 2017

BRIEF-Catalyst Biosciences Appoints Edward Williams To Its Board

* CATALYST BIOSCIENCES ANNOUNCES APPOINTMENT OF EDWARD WILLIAMS TO ITS BOARD OF DIRECTORS

14 Dec 2017

BRIEF-Catalyst biosciences Q3 loss per share $1.34

* Catalyst Biosciences reports third quarter 2017 operating & financial results and provides corporate update

02 Nov 2017

BRIEF-Catalyst Biosciences and Mosaic Biosciences enter into strategic collaboration

* Catalyst Biosciences and Mosaic Biosciences enter into strategic collaboration to develop intravitreal anti-complement factor 3 (c3) products for the treatment of dry amd and other retinal diseases

24 Oct 2017

BRIEF-Catalyst Biosciences Inc - ‍companies plan to have interim, top-line results by end of 2017

* Catalyst Biosciences granted FDA orphan drug designation for subcutaneous recombinant human Factor IX variant for treatment of hemophilia B

26 Sep 2017

BRIEF-Catalyst Biosciences announces successful completion of first subcutaneous dosing cohort in ongoing hemophilia B clinical trial

* Catalyst Biosciences announces successful completion of first subcutaneous dosing cohort in ongoing hemophilia B clinical trial

25 Sep 2017

BRIEF-Catalyst Biosciences Inc announces issuance of Asia patents covering Factor IX Hemophilia Program

* Catalyst Biosciences Inc - announces issuance of Asia patents covering factor IX Hemophilia Program Source text for Eikon: Further company coverage:

11 Sep 2017

Competitors

Earnings vs. Estimates